Phase III Study KEYNOTE-181: Pembrolizumab (KEYTRUDA (R)) Monotherapy for the Second-line Treatment of advanced Esophageal Cancer or Cancer of the esophagogastral Junction with PD-L1 Expression (CPS >= 10)-MedSci.cn

Phase III Study KEYNOTE-181: Pembrolizumab (KEYTRUDA (R)) Monotherapy for the Second-line Treatment of advanced Esophageal Cancer or Cancer of the esophagogastral Junction with PD-L1 Expression (CPS >= 10)

VISCERAL MEDICINE, 2019; 35 (6): 396

科室
- - 订阅+
  - 更多科室
工具
服务